

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT		Docket Number: 11245/46506		
Application Number To Be Assigned	Filing Date Herewith	Examiner Art Unit To Be Assigned To Be Assigned		
Invention Title ANTIBODIES SPECIFIC TO KDR AND USES THEREOF		Inventor(s) ZHU, et al.		

Address to:

Mail Stop Patent Application

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
- 2. Except as otherwise indicated, copies of the references are not enclosed since they were previously cited by or submitted to the Patent Office in prior patent application Serial Nos. 09/493,539, filed January 28, 2000 and 09/976,787, filed October 12, 2001, which are relied upon for an earlier filing date under 35 U.S.C. 120.

Dated: March 23, 2004

By:

Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON

One Broadway

New York, New York 10004

(212) 425-7200 (Telephone)

(212) 425-5288 (Facsimile)

CUSTOMER NO. 26646



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT		Docket Number: 11245/46506		
Application Number To Be Assigned	Filing Date Herewith	Examiner Art Unit To Be Assigned To Be Assigned		
Invention Title ANTIBODIES SPECIFIC TO KDR AND USES THEREOF		Inventor(s) ZHU, et al.		

Address to:

Mail Stop Patent Application

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
- 2. Except as otherwise indicated, copies of the references are not enclosed since they were previously cited by or submitted to the Patent Office in prior patent application Serial Nos. 09/493,539, filed January 28, 2000 and 09/976,787, filed October 12, 2001, which are relied upon for an earlier filing date under 35 U.S.C. 120.

Dated: March 23, 2004

By:

Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON

One Broadway

New York, New York 10004

(212) 425-7200 (Telephone)

(212) 425-5288 (Facsimile)

CUSTOMER NO. 26646

MAR 2 3 2004 2 3

SUPPLEMENTAL NEORMATION DISCLOSURE STATEMENT BY APPLICANT

Modified PTO Form 1449

Atty. Docket No. 11245/46505	Serial No. 09/976,787
Applicant Zhu et al.	
Filing Date October 12 2001	Group 1642

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,955,311	9/21/99	Rockwell et al.			
	5,837,242	11/98	Holliger et al.			
	5,861,499	1/19/99	Rockwell			
	5,851,999	12/28/98	Ullrich et al.			
	5,747,651	5/5/98	Lemischka			
	5,621,090	4/15/97	Lemischka			
	5,270,458	12/14/93	Lemischka			
	5,185,438	2/9/93	Lemischka			
	4,946,778	8/7/90	Ladner			

FOREIGN PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL						YES	NO
	WO 99 60025	November 25, 1999	PCT		_		
	WO 99 40118	August 12, 1999	PCŢ				
	WO 98 11223	March 19, 1998	PCT				
	WO 91 16353	October 31, 1991	PCT				
	EP 338745	3/1/95	Europe				
	EP 239400	8/3/94	Europe				
	WO 92/14748	9/3/92	PCT	_			
	WO 88/09344	12/1/88	PCT				
	2,085,291	1/31/94	Canada				
	EP 0332424	9/13/89	Europe				
	WO 95/21868	8/17/95	PCT				
	WO 94/11499	5/26/94	PCT				

EXAMINER	DOCUMENT	TRADEMARK			•	TRANSLATION
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	
	WO 94/10331	5/11/94	PCT			
	WO 94/10202	5/11/94	PCT			
	WO 93/21319	10/28/93	PCT			
	WO 93/12220	6/24/93	PCT			
	WO 93/11238	6/10/93	PCT			
	WO 92/01047	1/23/92	PCT			
	WO 91/02058	2/21/91	PCT			
	WO 89/09622	10/19/89	PCT			

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Hicklin et al. "Monoclonal Anti-Vascular Endothelial Growth Factor (VEGF) Receptor (KDR) Antibodies which are Inhibitors of VEGF Binding and Antagonists of VEGF-stimulated Signaling and Growth of Human Endothelial Cells" Proceedings of the Annual Meeting of the American Association for Cancer Research, March 1998, vol. 39, page 96, abstract
	Berkman, R. et al. (1993) J. Clin. Invest. 91: 153-159.
	Breier et al., (1992) Development (Camb.) 114:521.
	Brown et al., (1992) J. Exp. Med., 176:1375.
	Co, M.S. et al. (1991) Nature 351:501-502.
	Ferrara et al. (1992) Endocr. Rev. 13:18.
	Folkman, J. et al. (1987) Science 235:442-447.
	Kaipainen et al. (1993) J. Exp. Med. 178:2077-2088.
	Kim, K. et al., (1993) Nature 362:841-844.
	Klagsbrun, M. and D'Amore, P., (1991) Annual Rev. Physiol. 53:217-239.
	Lawrence, L.J., et al. (1998) FEBS Lett 425:479-84
	Leung, W. et al., (1989) Science 246:1306-1309.
	Matthews, et al. (1991) Proc. Natl. Acad. Sci. USA 88:9026-9030
	Millauer et al. (1993) Cell 72:835-846.
	Plate et al. (1993) Cancer Res. 53:5822-5827.
	Plate et al. (1992) Nature 359:845-848.
	Rockwell, P. et al., (1995) Molecular and Cellular Differentiation 3:315-355.

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.			
	Rockwell, P. et al., (1995) Molecular and Cellular Differentiation 3:91-109.			
	Shibuya et al., (1990) Oncogene 5:519-524.			
	Shweiki, D. et al. (1992) Nature 359: 843-845.			
	Terman et al. (1991) Oncogene 6:1677-1683.			
	Witte, L., et al. (1998) Cancer Metastasis Rev. 17:155-161.			
	Zhu, Z. et al (1998) Cancer Res. 58:3209-3214.			
	Zhu, Z. et al. (1999) Cancer Lett. 136:203-213.			
Examiner	Date Considered			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.